One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-1R. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-1R targeting therapy provides a new avenue toward treating liver cancer. © 2013 Chen et al, publisher and licensee Dove Medical Press Ltd.
Chen, X. H., Li, Z. Q., Peng, H., Jin, S. M., Fu, H. Q., Zhu, T. C., & Weng, X. G. (2013). Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer. OncoTargets and Therapy, 6, 527–530. https://doi.org/10.2147/OTT.S44162